APO Research
Talk to an analyst

APO RESEARCH · REPORT

CINV Existing and Pipeline Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global CINV Existing and Pipeline Drugs Industry Growth and Trends Forecast to 2032

20 December 202595 pages

Choose your research edition.

Industry ResearchCINV Existing and Pipeline Drugs Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal CINV Existing and Pipeline Drugs Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal CINV Existing and Pipeline Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CINV Existing and Pipeline Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal CINV Existing and Pipeline Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global CINV Existing and Pipeline Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for CINV Existing and Pipeline Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for CINV Existing and Pipeline Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for CINV Existing and Pipeline Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of CINV Existing and Pipeline Drugs include Merck, GlaxoSmithKline, Tesaro, Heron Therapeutics and Helsinn, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global CINV Existing and Pipeline Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The CINV Existing and Pipeline Drugs market size, estimates, and forecasts are presented in terms of sales volume (Kg) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global CINV Existing and Pipeline Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to CINV Existing and Pipeline Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global CINV Existing and Pipeline Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

CINV Existing and Pipeline Drugs Market by Company

Merck

GlaxoSmithKline

Tesaro

Heron Therapeutics

Helsinn

CINV Existing and Pipeline Drugs Segment by Type

Akynzeo

Aloxi

Emend

Kytril Generic

Rolapitant

SUSTOL

Zofran Generic

CINV Existing and Pipeline Drugs Segment by Application

Specialty Clinics

Diagnostic Centers Therapeutics

Hospital Pharmacies

Hospitals

Drugstores

CINV Existing and Pipeline Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CINV Existing and Pipeline Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CINV Existing and Pipeline Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CINV Existing and Pipeline Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of CINV Existing and Pipeline Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of CINV Existing and Pipeline Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Akynzeo Table 2. Major Company of Aloxi Table 3. Major Company of Emend Table 4. Major Company of Kytril Generic Table 5. Major Company of Rolapitant Table 6. Major Company of SUSTOL Table 7. Major Company of Zofran Generic Table 8. Global CINV Existing and Pipeline Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 9. Global CINV Existing and Pipeline Drugs Sales by Type (2021-2026) & (Kg) Table 10. Global CINV Existing and Pipeline Drugs Sales Market Share in Volume by Type (2021-2026) Table 11. Global CINV Existing and Pipeline Drugs Sales by Type (2021-2026) & (US$ Million) Table 12. Global CINV Existing and Pipeline Drugs Sales Market Share in Value by Type (2021-2026) Table 13. Global CINV Existing and Pipeline Drugs Price by Type (2021-2026) & (US$/Kg) Table 14. Global CINV Existing and Pipeline Drugs Sales by Type (2027-2032) & (Kg) Table 15. Global CINV Existing and Pipeline Drugs Sales Market Share in Volume by Type (2027-2032) Table 16. Global CINV Existing and Pipeline Drugs Sales by Type (2027-2032) & (US$ Million) Table 17. Global CINV Existing and Pipeline Drugs Sales Market Share in Value by Type (2027-2032) Table 18. Global CINV Existing and Pipeline Drugs Price by Type (2027-2032) & (US$/Kg) Table 19. North America CINV Existing and Pipeline Drugs Sales by Type (2021-2026) & (Kg) Table 20. North America CINV Existing and Pipeline Drugs Sales by Type (2021-2026) & (US$ Million) Table 21. Europe CINV Existing and Pipeline Drugs Sales by Type (2021-2026) & (Kg) Table 22. Europe CINV Existing and Pipeline Drugs Sales by Type (2021-2026) & (US$ Million) Table 23. Asia-Pacific CINV Existing and Pipeline Drugs Sales by Type (2021-2026) & (Kg) Table 24. Asia-Pacific CINV Existing and Pipeline Drugs Sales by Type (2021-2026) & (US$ Million) Table 25. Latin America CINV Existing and Pipeline Drugs Sales by Type (2021-2026) & (Kg) Table 26. Latin America CINV Existing and Pipeline Drugs Sales by Type (2021-2026) & (US$ Million) Table 27. Middle East and Africa CINV Existing and Pipeline Drugs Sales by Type (2021-2026) & (Kg) Table 28. Middle East and Africa CINV Existing and Pipeline Drugs Sales by Type (2021-2026) & (US$ Million) Table 29. CINV Existing and Pipeline Drugs Industry Trends Table 30. CINV Existing and Pipeline Drugs Industry Drivers Table 31. CINV Existing and Pipeline Drugs Industry Opportunities and Challenges Table 32. CINV Existing and Pipeline Drugs Industry Restraints Table 33. Global CINV Existing and Pipeline Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 34. Global CINV Existing and Pipeline Drugs Revenue Market Share by Company (2021-2026) Table 35. Global CINV Existing and Pipeline Drugs Sales by Company (2021-2026) & (Kg) Table 36. Global CINV Existing and Pipeline Drugs Sales Share by Company (2021-2026) Table 37. Global CINV Existing and Pipeline Drugs Market Price by Company (2021-2026) & (US$/Kg) Table 38. Global CINV Existing and Pipeline Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 39. Global CINV Existing and Pipeline Drugs Major Company Production Sites and Headquarters Table 40. Global CINV Existing and Pipeline Drugs Company, Product Type & Application Table 41. Global CINV Existing and Pipeline Drugs Company Establishment Date Table 42. Global Company Market Concentration Ratio (CR5 and HHI) Table 43. Global CINV Existing and Pipeline Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 44. Global CINV Existing and Pipeline Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 45. Global CINV Existing and Pipeline Drugs Sales by Region (2021-2026) & (Kg) Table 46. Global CINV Existing and Pipeline Drugs Sales Market Share in Volume by Region (2021-2026) Table 47. Global CINV Existing and Pipeline Drugs Sales by Region (2021-2026) & (US$ Million) Table 48. Global CINV Existing and Pipeline Drugs Sales Market Share in Value by Region (2021-2026) Table 49. Global CINV Existing and Pipeline Drugs Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 50. Global CINV Existing and Pipeline Drugs Sales by Region (2027-2032) & (Kg) Table 51. Global CINV Existing and Pipeline Drugs Sales Market Share in Volume by Region (2027-2032) Table 52. Global CINV Existing and Pipeline Drugs Sales by Region (2027-2032) & (US$ Million) Table 53. Global CINV Existing and Pipeline Drugs Sales Market Share in Value by Region (2027-2032) Table 54. Global CINV Existing and Pipeline Drugs Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2027-2032) Table 55. Global CINV Existing and Pipeline Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 56. Global CINV Existing and Pipeline Drugs Sales by Application (2021-2026) & (Kg) Table 57. Global CINV Existing and Pipeline Drugs Sales Market Share in Volume by Application (2021-2026) Table 58. Global CINV Existing and Pipeline Drugs Sales by Application (2021-2026) & (US$ Million) Table 59. Global CINV Existing and Pipeline Drugs Sales Market Share in Value by Application (2021-2026) Table 60. Global CINV Existing and Pipeline Drugs Price by Application (2021-2026) & (US$/Kg) Table 61. Global CINV Existing and Pipeline Drugs Sales by Application (2027-2032) & (Kg) Table 62. Global CINV Existing and Pipeline Drugs Sales Market Share in Volume by Application (2027-2032) Table 63. Global CINV Existing and Pipeline Drugs Sales by Application (2027-2032) & (US$ Million) Table 64. Global CINV Existing and Pipeline Drugs Sales Market Share in Value by Application (2027-2032) Table 65. Global CINV Existing and Pipeline Drugs Price by Application (2027-2032) & (US$/Kg) Table 66. North America CINV Existing and Pipeline Drugs Sales by Application (2021-2026) & (Kg) Table 67. North America CINV Existing and Pipeline Drugs Sales by Application (2021-2026) & (US$ Million) Table 68. Europe CINV Existing and Pipeline Drugs Sales by Application (2021-2026) & (Kg) Table 69. Europe CINV Existing and Pipeline Drugs Sales by Application (2021-2026) & (US$ Million) Table 70. Asia-Pacific CINV Existing and Pipeline Drugs Sales by Application (2021-2026) & (Kg) Table 71. Asia-Pacific CINV Existing and Pipeline Drugs Sales by Application (2021-2026) & (US$ Million) Table 72. Latin America CINV Existing and Pipeline Drugs Sales by Application (2021-2026) & (Kg) Table 73. Latin America CINV Existing and Pipeline Drugs Sales by Application (2021-2026) & (US$ Million) Table 74. Middle East and Africa CINV Existing and Pipeline Drugs Sales by Application (2021-2026) & (Kg) Table 75. Middle East and Africa CINV Existing and Pipeline Drugs Sales by Application (2021-2026) & (US$ Million) Table 76. Merck Company Information Table 77. Merck Business Overview Table 78. Merck CINV Existing and Pipeline Drugs Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 79. Merck CINV Existing and Pipeline Drugs Product Portfolio Table 80. Merck Recent Development Table 81. GlaxoSmithKline Company Information Table 82. GlaxoSmithKline Business Overview Table 83. GlaxoSmithKline CINV Existing and Pipeline Drugs Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 84. GlaxoSmithKline CINV Existing and Pipeline Drugs Product Portfolio Table 85. GlaxoSmithKline Recent Development Table 86. Tesaro Company Information Table 87. Tesaro Business Overview Table 88. Tesaro CINV Existing and Pipeline Drugs Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 89. Tesaro CINV Existing and Pipeline Drugs Product Portfolio Table 90. Tesaro Recent Development Table 91. Heron Therapeutics Company Information Table 92. Heron Therapeutics Business Overview Table 93. Heron Therapeutics CINV Existing and Pipeline Drugs Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 94. Heron Therapeutics CINV Existing and Pipeline Drugs Product Portfolio Table 95. Heron Therapeutics Recent Development Table 96. Helsinn Company Information Table 97. Helsinn Business Overview Table 98. Helsinn CINV Existing and Pipeline Drugs Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 99. Helsinn CINV Existing and Pipeline Drugs Product Portfolio Table 100. Helsinn Recent Development Table 101. North America CINV Existing and Pipeline Drugs Market Size Growth Rate (CAGR) by Country (Kg): 2021 VS 2025 VS 2032 Table 102. North America CINV Existing and Pipeline Drugs Sales by Country (2021-2026) & (Kg) Table 103. North America CINV Existing and Pipeline Drugs Sales Market Share by Country (2021-2026) Table 104. North America CINV Existing and Pipeline Drugs Sales Forecast by Country (2027-2032) & (Kg) Table 105. North America CINV Existing and Pipeline Drugs Sales Market Share Forecast by Country (2027-2032) Table 106. North America CINV Existing and Pipeline Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 107. North America CINV Existing and Pipeline Drugs Market Size by Country (2021-2026) & (US$ Million) Table 108. North America CINV Existing and Pipeline Drugs Market Share by Country (2021-2026) Table 109. North America CINV Existing and Pipeline Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 110. North America CINV Existing and Pipeline Drugs Market Share Forecast by Country (2027-2032) Table 111. Europe CINV Existing and Pipeline Drugs Market Size Growth Rate (CAGR) by Country (Kg): 2021 VS 2025 VS 2032 Table 112. Europe CINV Existing and Pipeline Drugs Sales by Country (2021-2026) & (Kg) Table 113. Europe CINV Existing and Pipeline Drugs Sales Market Share by Country (2021-2026) Table 114. Europe CINV Existing and Pipeline Drugs Sales Forecast by Country (2027-2032) & (Kg) Table 115. Europe CINV Existing and Pipeline Drugs Sales Market Share Forecast by Country (2027-2032) Table 116. Europe CINV Existing and Pipeline Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 117. Europe CINV Existing and Pipeline Drugs Market Size by Country (2021-2026) & (US$ Million) Table 118. Europe CINV Existing and Pipeline Drugs Market Share by Country (2021-2026) Table 119. Europe CINV Existing and Pipeline Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 120. Europe CINV Existing and Pipeline Drugs Market Share Forecast by Country (2027-2032) Table 121. Asia-Pacific CINV Existing and Pipeline Drugs Market Size Growth Rate (CAGR) by Country (Kg): 2021 VS 2025 VS 2032 Table 122. Asia-Pacific CINV Existing and Pipeline Drugs Sales by Country (2021-2026) & (Kg) Table 123. Asia-Pacific CINV Existing and Pipeline Drugs Sales Market Share by Country (2021-2026) Table 124. Asia-Pacific CINV Existing and Pipeline Drugs Sales Forecast by Country (2027-2032) & (Kg) Table 125. Asia-Pacific CINV Existing and Pipeline Drugs Sales Market Share Forecast by Country (2027-2032) Table 126. Asia-Pacific CINV Existing and Pipeline Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 127. Asia-Pacific CINV Existing and Pipeline Drugs Market Size by Country (2021-2026) & (US$ Million) Table 128. Asia-Pacific CINV Existing and Pipeline Drugs Market Share by Country (2021-2026) Table 129. Asia-Pacific CINV Existing and Pipeline Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 130. Asia-Pacific CINV Existing and Pipeline Drugs Market Share Forecast by Country (2027-2032) Table 131. Latin America CINV Existing and Pipeline Drugs Market Size Growth Rate (CAGR) by Country (Kg): 2021 VS 2025 VS 2032 Table 132. Latin America CINV Existing and Pipeline Drugs Sales by Country (2021-2026) & (Kg) Table 133. Latin America CINV Existing and Pipeline Drugs Sales Market Share by Country (2021-2026) Table 134. Latin America CINV Existing and Pipeline Drugs Sales Forecast by Country (2027-2032) & (Kg) Table 135. Latin America CINV Existing and Pipeline Drugs Sales Market Share Forecast by Country (2027-2032) Table 136. Latin America CINV Existing and Pipeline Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. Latin America CINV Existing and Pipeline Drugs Market Size by Country (2021-2026) & (US$ Million) Table 138. Latin America CINV Existing and Pipeline Drugs Market Share by Country (2021-2026) Table 139. Latin America CINV Existing and Pipeline Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. Latin America CINV Existing and Pipeline Drugs Market Share Forecast by Country (2027-2032) Table 141. Middle East and Africa CINV Existing and Pipeline Drugs Market Size Growth Rate (CAGR) by Country (Kg): 2021 VS 2025 VS 2032 Table 142. Middle East and Africa CINV Existing and Pipeline Drugs Sales by Country (2021-2026) & (Kg) Table 143. Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share by Country (2021-2026) Table 144. Middle East and Africa CINV Existing and Pipeline Drugs Sales Forecast by Country (2027-2032) & (Kg) Table 145. Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share Forecast by Country (2027-2032) Table 146. Middle East and Africa CINV Existing and Pipeline Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. Middle East and Africa CINV Existing and Pipeline Drugs Market Size by Country (2021-2026) & (US$ Million) Table 148. Middle East and Africa CINV Existing and Pipeline Drugs Market Share by Country (2021-2026) Table 149. Middle East and Africa CINV Existing and Pipeline Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. Middle East and Africa CINV Existing and Pipeline Drugs Market Share Forecast by Country (2027-2032) Table 151. Key Raw Materials Table 152. Raw Materials Key Suppliers Table 153. CINV Existing and Pipeline Drugs Distributors List Table 154. CINV Existing and Pipeline Drugs Customers List Table 155. Research Programs/Design for This Report Table 156. Authors List of This Report Table 157. Secondary Sources Table 158. Primary Sources List of Figures Figure 1. CINV Existing and Pipeline Drugs Image Figure 2. Global CINV Existing and Pipeline Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CINV Existing and Pipeline Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global CINV Existing and Pipeline Drugs Sales (2021-2032) & (Kg) Figure 5. Akynzeo Image Figure 6. Global Akynzeo Sales YoY Growth (2021-2032) & (Kg) Figure 7. Aloxi Image Figure 8. Global Aloxi Sales YoY Growth (2021-2032) & (Kg) Figure 9. Emend Image Figure 10. Global Emend Sales YoY Growth (2021-2032) & (Kg) Figure 11. Kytril Generic Image Figure 12. Global Kytril Generic Sales YoY Growth (2021-2032) & (Kg) Figure 13. Rolapitant Image Figure 14. Global Rolapitant Sales YoY Growth (2021-2032) & (Kg) Figure 15. SUSTOL Image Figure 16. Global SUSTOL Sales YoY Growth (2021-2032) & (Kg) Figure 17. Zofran Generic Image Figure 18. Global Zofran Generic Sales YoY Growth (2021-2032) & (Kg) Figure 19. Global CINV Existing and Pipeline Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 20. Global CINV Existing and Pipeline Drugs Market Share by Type 2025 VS 2032 Figure 21. North America CINV Existing and Pipeline Drugs Sales Market Share in Volume by Type in 2025 Figure 22. North America CINV Existing and Pipeline Drugs Sales Market Share in Value by Type in 2025 Figure 23. Europe CINV Existing and Pipeline Drugs Sales Market Share in Volume by Type in 2025 Figure 24. Europe CINV Existing and Pipeline Drugs Sales Market Share in Value by Type in 2025 Figure 25. Asia-Pacific CINV Existing and Pipeline Drugs Sales Market Share in Volume by Type in 2025 Figure 26. Asia-Pacific CINV Existing and Pipeline Drugs Sales Market Share in Value by Type in 2025 Figure 27. Latin America CINV Existing and Pipeline Drugs Sales Market Share in Volume by Type in 2025 Figure 28. Latin America CINV Existing and Pipeline Drugs Sales Market Share in Value by Type in 2025 Figure 29. Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share in Volume by Type in 2025 Figure 30. Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share in Value by Type in 2025 Figure 31. Global Top 5 and 10 CINV Existing and Pipeline Drugs Players Market Share by Revenue in 2025 Figure 32. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 33. Specialty Clinics Image Figure 34. Global Specialty Clinics Sales YoY Growth (2021-2032) & (Kg) Figure 35. Diagnostic Centers Therapeutics Image Figure 36. Global Diagnostic Centers Therapeutics Sales YoY Growth (2021-2032) & (Kg) Figure 37. Hospital Pharmacies Image Figure 38. Global Hospital Pharmacies Sales YoY Growth (2021-2032) & (Kg) Figure 39. Hospitals Image Figure 40. Global Hospitals Sales YoY Growth (2021-2032) & (Kg) Figure 41. Drugstores Image Figure 42. Global Drugstores Sales YoY Growth (2021-2032) & (Kg) Figure 43. Global CINV Existing and Pipeline Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 44. Global CINV Existing and Pipeline Drugs Market Share by Application 2025 VS 2032 Figure 45. North America CINV Existing and Pipeline Drugs Sales Market Share in Volume by Application in 2025 Figure 46. North America CINV Existing and Pipeline Drugs Sales Market Share in Value by Application in 2025 Figure 47. Europe CINV Existing and Pipeline Drugs Sales Market Share in Volume by Application in 2025 Figure 48. Europe CINV Existing and Pipeline Drugs Sales Market Share in Value by Application in 2025 Figure 49. Asia-Pacific CINV Existing and Pipeline Drugs Sales Market Share in Volume by Application in 2025 Figure 50. Asia-Pacific CINV Existing and Pipeline Drugs Sales Market Share in Value by Application in 2025 Figure 51. Latin America CINV Existing and Pipeline Drugs Sales Market Share in Volume by Application in 2025 Figure 52. Latin America CINV Existing and Pipeline Drugs Sales Market Share in Value by Application in 2025 Figure 53. Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share in Volume by Application in 2025 Figure 54. Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share in Value by Application in 2025 Figure 55. North America CINV Existing and Pipeline Drugs Sales by Country: 2021 VS 2025 VS 2032 (Kg) Figure 56. North America CINV Existing and Pipeline Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. North America CINV Existing and Pipeline Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. North America CINV Existing and Pipeline Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe CINV Existing and Pipeline Drugs Sales by Country: 2021 VS 2025 VS 2032 (Kg) Figure 60. Europe CINV Existing and Pipeline Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe CINV Existing and Pipeline Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Europe CINV Existing and Pipeline Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific CINV Existing and Pipeline Drugs Sales by Country: 2021 VS 2025 VS 2032 (Kg) Figure 64. Asia-Pacific CINV Existing and Pipeline Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific CINV Existing and Pipeline Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Asia-Pacific CINV Existing and Pipeline Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Latin America CINV Existing and Pipeline Drugs Sales by Country: 2021 VS 2025 VS 2032 (Kg) Figure 68. Latin America CINV Existing and Pipeline Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 69. Latin America CINV Existing and Pipeline Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 70. Latin America CINV Existing and Pipeline Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 71. Middle East and Africa CINV Existing and Pipeline Drugs Sales by Country: 2021 VS 2025 VS 2032 (Kg) Figure 72. Middle East and Africa CINV Existing and Pipeline Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 73. Middle East and Africa CINV Existing and Pipeline Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 74. Middle East and Africa CINV Existing and Pipeline Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 75. CINV Existing and Pipeline Drugs Value Chain Figure 76. Key Raw Materials Price Figure 77. Manufacturing Cost Structure Figure 78. CINV Existing and Pipeline Drugs Production Mode & Process Figure 79. Direct Comparison with Distribution Share Figure 80. Distributors Profiles Figure 81. Years Considered Figure 82. Research Process Figure 83. Key Executives Interviewed

Scope & coverage.

Types
  • Akynzeo
  • Aloxi
  • Emend
  • Kytril Generic
  • Rolapitant
  • SUSTOL
  • Zofran Generic
Applications
  • Specialty Clinics
  • Diagnostic Centers Therapeutics
  • Hospital Pharmacies
  • Hospitals
  • Drugstores
Companies covered
  • Merck
  • GlaxoSmithKline
  • Tesaro
  • Heron Therapeutics
  • Helsinn

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global CINV Existing and Pipeline Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global CINV Existing and Pipeline Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 CINV Existing and Pipeline Drugs Market by Type
  6. 1.3.1 Akynzeo
  7. 1.3.2 Aloxi
  8. 1.3.3 Emend
  9. 1.3.4 Kytril Generic
  10. 1.3.5 Rolapitant
  11. 1.3.6 SUSTOL
  12. 1.3.7 Zofran Generic
  13. 1.4 Global CINV Existing and Pipeline Drugs Market Size by Type
  14. 1.4.1 Global CINV Existing and Pipeline Drugs Market Size Overview by Type (2021-2032)
  15. 1.4.2 Global CINV Existing and Pipeline Drugs Historic Market Size Review by Type (2021-2026)
  16. 1.4.3 Global CINV Existing and Pipeline Drugs Forecasted Market Size by Type (2027-2032)
  17. 1.5 Key Regions Market Size by Type
  18. 1.5.1 North America CINV Existing and Pipeline Drugs Sales Breakdown by Type (2021-2026)
  19. 1.5.2 Europe CINV Existing and Pipeline Drugs Sales Breakdown by Type (2021-2026)
  20. 1.5.3 Asia-Pacific CINV Existing and Pipeline Drugs Sales Breakdown by Type (2021-2026)
  21. 1.5.4 South America CINV Existing and Pipeline Drugs Sales Breakdown by Type (2021-2026)
  22. 1.5.5 Middle East and Africa CINV Existing and Pipeline Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 CINV Existing and Pipeline Drugs Industry Trends
  2. 2.2 CINV Existing and Pipeline Drugs Industry Drivers
  3. 2.3 CINV Existing and Pipeline Drugs Industry Opportunities and Challenges
  4. 2.4 CINV Existing and Pipeline Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by CINV Existing and Pipeline Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by CINV Existing and Pipeline Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by CINV Existing and Pipeline Drugs Price (2021-2026)
  4. 3.4 Global CINV Existing and Pipeline Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global CINV Existing and Pipeline Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global CINV Existing and Pipeline Drugs Company, Product Type & Application
  7. 3.7 Global CINV Existing and Pipeline Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global CINV Existing and Pipeline Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 CINV Existing and Pipeline Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 CINV Existing and Pipeline Drugs Tier 1, Tier 2, and Tier 3
4 CINV Existing and Pipeline Drugs Regional Status and Outlook
  1. 4.1 Global CINV Existing and Pipeline Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global CINV Existing and Pipeline Drugs Historic Market Size by Region
  3. 4.2.1 Global CINV Existing and Pipeline Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global CINV Existing and Pipeline Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global CINV Existing and Pipeline Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global CINV Existing and Pipeline Drugs Forecasted Market Size by Region
  7. 4.3.1 Global CINV Existing and Pipeline Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global CINV Existing and Pipeline Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global CINV Existing and Pipeline Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 CINV Existing and Pipeline Drugs by Application
  1. 5.1 CINV Existing and Pipeline Drugs Market by Application
  2. 5.1.1 Specialty Clinics
  3. 5.1.2 Diagnostic Centers Therapeutics
  4. 5.1.3 Hospital Pharmacies
  5. 5.1.4 Hospitals
  6. 5.1.5 Drugstores
  7. 5.2 Global CINV Existing and Pipeline Drugs Market Size by Application
  8. 5.2.1 Global CINV Existing and Pipeline Drugs Market Size Overview by Application (2021-2032)
  9. 5.2.2 Global CINV Existing and Pipeline Drugs Historic Market Size Review by Application (2021-2026)
  10. 5.2.3 Global CINV Existing and Pipeline Drugs Forecasted Market Size by Application (2027-2032)
  11. 5.3 Key Regions Market Size by Application
  12. 5.3.1 North America CINV Existing and Pipeline Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.2 Europe CINV Existing and Pipeline Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.3 Asia-Pacific CINV Existing and Pipeline Drugs Sales Breakdown by Application (2021-2026)
  15. 5.3.4 South America CINV Existing and Pipeline Drugs Sales Breakdown by Application (2021-2026)
  16. 5.3.5 Middle East and Africa CINV Existing and Pipeline Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Merck
  2. 6.1.1 Merck Company Information
  3. 6.1.2 Merck Business Overview
  4. 6.1.3 Merck CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Merck CINV Existing and Pipeline Drugs Product Portfolio
  6. 6.1.5 Merck Recent Developments
  7. 6.2 GlaxoSmithKline
  8. 6.2.1 GlaxoSmithKline Company Information
  9. 6.2.2 GlaxoSmithKline Business Overview
  10. 6.2.3 GlaxoSmithKline CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 GlaxoSmithKline CINV Existing and Pipeline Drugs Product Portfolio
  12. 6.2.5 GlaxoSmithKline Recent Developments
  13. 6.3 Tesaro
  14. 6.3.1 Tesaro Company Information
  15. 6.3.2 Tesaro Business Overview
  16. 6.3.3 Tesaro CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Tesaro CINV Existing and Pipeline Drugs Product Portfolio
  18. 6.3.5 Tesaro Recent Developments
  19. 6.4 Heron Therapeutics
  20. 6.4.1 Heron Therapeutics Company Information
  21. 6.4.2 Heron Therapeutics Business Overview
  22. 6.4.3 Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Heron Therapeutics CINV Existing and Pipeline Drugs Product Portfolio
  24. 6.4.5 Heron Therapeutics Recent Developments
  25. 6.5 Helsinn
  26. 6.5.1 Helsinn Company Information
  27. 6.5.2 Helsinn Business Overview
  28. 6.5.3 Helsinn CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Helsinn CINV Existing and Pipeline Drugs Product Portfolio
  30. 6.5.5 Helsinn Recent Developments
7 North America by Country
  1. 7.1 North America CINV Existing and Pipeline Drugs Sales by Country
  2. 7.1.1 North America CINV Existing and Pipeline Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America CINV Existing and Pipeline Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America CINV Existing and Pipeline Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America CINV Existing and Pipeline Drugs Market Size by Country
  6. 7.2.1 North America CINV Existing and Pipeline Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America CINV Existing and Pipeline Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America CINV Existing and Pipeline Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe CINV Existing and Pipeline Drugs Sales by Country
  2. 8.1.1 Europe CINV Existing and Pipeline Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe CINV Existing and Pipeline Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe CINV Existing and Pipeline Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe CINV Existing and Pipeline Drugs Market Size by Country
  6. 8.2.1 Europe CINV Existing and Pipeline Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe CINV Existing and Pipeline Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe CINV Existing and Pipeline Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific CINV Existing and Pipeline Drugs Sales by Country
  2. 9.1.1 Asia-Pacific CINV Existing and Pipeline Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific CINV Existing and Pipeline Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific CINV Existing and Pipeline Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific CINV Existing and Pipeline Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific CINV Existing and Pipeline Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific CINV Existing and Pipeline Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific CINV Existing and Pipeline Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America CINV Existing and Pipeline Drugs Sales by Country
  2. 10.1.1 South America CINV Existing and Pipeline Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America CINV Existing and Pipeline Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America CINV Existing and Pipeline Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America CINV Existing and Pipeline Drugs Market Size by Country
  6. 10.2.1 South America CINV Existing and Pipeline Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America CINV Existing and Pipeline Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America CINV Existing and Pipeline Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa CINV Existing and Pipeline Drugs Sales by Country
  2. 11.1.1 Middle East and Africa CINV Existing and Pipeline Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa CINV Existing and Pipeline Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa CINV Existing and Pipeline Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa CINV Existing and Pipeline Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa CINV Existing and Pipeline Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa CINV Existing and Pipeline Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa CINV Existing and Pipeline Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 CINV Existing and Pipeline Drugs Value Chain Analysis
  2. 12.1.1 CINV Existing and Pipeline Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 CINV Existing and Pipeline Drugs Production Mode & Process
  7. 12.2 CINV Existing and Pipeline Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 CINV Existing and Pipeline Drugs Distributors
  10. 12.2.3 CINV Existing and Pipeline Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst